RCS - Synairgen plc - Presentation at ECCMID

SynairgenAnnouncement

25/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1312Ja&default-theme=true

RNS Number : 1312J  Synairgen plc  25 April 2022

 

Synairgen plc

('Synairgen' or the 'Company')

Synairgen Presented Phase 2 Sub-group Analysis for SNG001 in COVID-19 at the
European Congress of Clinical Microbiology & Infectious Diseases

 

Southampton, UK - 25 April 2022: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the broad-spectrum antiviral protein interferon beta, presented the
sub-group analysis from its Phase 2, SG016 study on Saturday 23 April in an
oral presentation at the 32nd European Congress of Clinical Microbiology &
Infectious Diseases (ECCMID), held in Lisbon, Portugal from 23-26 April 2022.

The positive results of this Phase 2 study (SG016) in the hospital setting
were first announced in July 2020 and published in The Lancet Respiratory
Medicine in November 2020.

ECCMID 2022:

Oral Presentation:

Title: Effects of Inhaled interferon beta on hospitalised COVID-19 patients
receiving supplemental oxygen

Abstract Number: 02567

Session type: 1-Hour Mini-oral Flash Session

Session name: COVID-19 treatment insights and advances

Session date and time: 23 April 2022 at 11:00 WEST

The poster presentation is now available on the Synairgen website. For further
information on ECCMID visit: https://www.eccmid.org/ (https://www.eccmid.org/)

ATS 2022:

Further analysis of the SPRINTER trial data will be presented at the ATS 2022
International Conference, being held between 13-18 May 2022 in San Francisco.

For further enquiries, please contact:

Synairgen plc

Brooke Clarke, Head of Communications

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Namrata Taak

cscsynairgen@consilium-comms.com (mailto:cscsynairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)

Tel: +1 516-606-6545

 

Notes for Editors

About the Phase 2 study (SG016, NCT04385095)

SG016 was a double-blind, placebo-controlled trial. The 220-patient trial
comprised c. 100 patients initiated in hospital and 120 patients initiated in
the home setting. The patients that participated in the hospital setting,
which completed recruitment in May 2020, were recruited across a number of NHS
trusts and the trial had been adopted by the NIHR Respiratory Translational
Research Collaboration which is comprised of leading centres in respiratory
medicine in the UK whose internationally recognised experts are working
together to accelerate development and discovery for COVID-19.

About SNG001

SNG001 is a pH-neutral formulation of interferon-beta (IFN-beta) for
inhalation that is delivered directly into the lungs using a mesh nebuliser,
currently being investigated as a potential host-directed antiviral treatment
for COVID-19 patients.

The SARS-CoV-2 virus has been shown to suppress the production of IFN-beta, a
naturally occurring protein that orchestrates the body's antiviral defences,
with the aim of evading host immune responses. By administering IFN-beta into
the lungs, the aim is to correct this deficiency, potentially switching back
on the lungs' antiviral pathways to clear the virus. SNG001 has been shown to
demonstrate potent in vitro antiviral activity against a broad range of
viruses including COVID-19 and Alpha, Beta, Gamma, Delta and Omicron
variants.

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially
the first host-targeted, broad-spectrum antiviral treatment delivered directly
into the lungs. SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent
Public Health study by the UK's National Institute for Health Research (NIHR).
The topline data from Synairgen's Phase 3 clinical programme evaluating SNG001
in patients across 17 countries was announced in February 2022 and detailed
analysis of the data is ongoing.

Founded by University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG).
For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABZLLLLZLBBBQ